Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402459 | 0.82 | MEN1 (0.58) | USP2TSHRATMHSD17B10SMN1; SMN2 | |
| SCHEMBL4509344 | 0.81 | USP2 (0.64) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL4493204 | 0.81 | USP2 (0.64) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL4495691 | 0.81 | USP2 (0.64) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL709506 | 0.80 | USP2 (1.00) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL14168302 | 0.77 | USP2 (0.58) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL11185 | 0.76 | USP2 (0.75) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL4388830 | 0.76 | USP2 (0.75) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL2978112 | 0.76 | USP2 (0.75) | USP2ALDH1A1TSHRL3MBTL1ANPEP | |
| SCHEMBL4384132 | 0.76 | USP2 (0.75) | USP2ALDH1A1TSHRL3MBTL1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166982-A1 | Isotopically labelly indlinone derivatives and process for their preparation | PFIZER ITALIA S.R.L. (IT) | 2006-07-27 | — | — | US | claimed |
| EP-1542734-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Pharmacia Italia S.p.A. (IT) | 2005-06-22 | — | — | EP | claimed |
| WO-2004012776-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-12 | — | — | WO | claimed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2849756-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | Novartis AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| EP-2750670-A1 | PI3K INHIBITOR FOR USE IN THE TREATMENT OF BONE CANCER OR FOR PREVENTING METASTATIC DISSEMINATION PRIMARY CANCER CELLS INTO THE BONE | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013173283-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004012776-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | USP2 3305/4885ALDH1A1 3069/4885TSHR 3937/4885 |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | USP2 4546/4885ALDH1A1 3308/4885TSHR 4015/4885 |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | PIK3CA, AKT3, AKT2 | USP2 1722/4885ALDH1A1 3526/4885TSHR 3631/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | USP2 2247/4885ALDH1A1 4016/4885TSHR 3873/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | USP2 1153/4885ALDH1A1 1173/4885TSHR 2747/4885 |
| US-20060166982-A1 | Isotopically labelly indlinone derivatives and process for their preparation | CYP3A5, SLC10A2, TMEM14C | USP2 4195/4885ALDH1A1 440/4885TSHR 2996/4885 |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | USP2 4385/4885ALDH1A1 3907/4885TSHR 4317/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | USP2 4546/4885ALDH1A1 3308/4885TSHR 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.